Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index; 19 of the 36 sources its claims cite were checked for support.
Abstract
BACKGROUND: Diabetes mellitus is associated with an increased risk of cardiovascular events. Aspirin use reduces the risk of occlusive vascular events but increases the risk of bleeding; the balance of benefits and hazards for the prevention of first cardiovascular events in patients with diabetes is unclear. METHODS: We randomly assigned adults who had diabetes but no evident cardiovascular disease to receive aspirin at a dose of 100 mg daily or matching placebo. The primary efficacy outcome was the first serious vascular event (i.e., myocardial infarction, stroke or transient ischemic attack, or death from any vascular cause, excluding any confirmed intracranial hemorrhage). The primary safety outcome was the first major bleeding event (i.e., intracranial hemorrhage, sight-threatening bleeding event in the eye, gastrointestinal bleeding, or other serious bleeding). Secondary outcomes included gastrointestinal tract cancer. RESULTS: A total of 15,480 participants underwent randomization. During a mean follow-up of 7.4 years, serious vascular events occurred in a significantly lower percentage of participants in the aspirin group than in the placebo group (658 participants [8.5%] vs. 743 [9.6%]; rate ratio, 0.88; 95% confidence interval [CI], 0.79 to 0.97; P=0.01). In contrast, major bleeding events occurred in 314 participants (4.1%) in the aspirin group, as compared with 245 (3.2%) in the placebo group (rate ratio, 1.29; 95% CI, 1.09 to 1.52; P=0.003), with most of the excess being gastrointestinal bleeding and other extracranial bleeding. There was no significant difference between the aspirin group and the placebo group in the incidence of gastrointestinal tract cancer (157 participants [2.0%] and 158 [2.0%], respectively) or all cancers (897 [11.6%] and 887 [11.5%]); long-term follow-up for these outcomes is planned. CONCLUSIONS: Aspirin use prevented serious vascular events in persons who had diabetes and no evident cardiovascular disease at trial entry, but it also caused major bleeding events. The absolute benefits were largely counterbalanced by the bleeding hazard. (Funded by the British Heart Foundation and others; ASCEND Current Controlled Trials number, ISRCTN60635500 ; ClinicalTrials.gov number, NCT00135226 .).
Overview
CoChat Summary
TL;DR
In adults with diabetes and no evident cardiovascular disease, low-dose aspirin reduced serious vascular events but increased major bleeding, with absolute benefits largely counterbalanced by bleeding hazards. Aspirin did not reduce gastrointestinal or overall cancer incidence over a mean follow-up of 7.4 years.
Key findings
- Serious vascular events occurred in 658 aspirin-group participants (8.5%) vs. 743 placebo-group participants (9.6%) (rate ratio, 0.88; 95% CI, 0.79 to 0.97; P=0.01).
- Major bleeding occurred in 314 aspirin-group participants (4.1%) vs. 245 placebo-group participants (3.2%) (rate ratio, 1.29; 95% CI, 1.09 to 1.52; P=0.003), mostly gastrointestinal and other extracranial bleeding.
- No significant between-group difference was found for gastrointestinal tract cancer (157 [2.0%] vs. 158 [2.0%]) or any cancer (897 [11.6%] vs. 887 [11.5%]).
- Absolute effects: 91 patients would need to be treated to avoid a serious vascular event over 7.4 years, and 112 to cause a major bleeding event.
Methods
- Randomized trial of 15,480 adults with diabetes but no evident cardiovascular disease, assigned to aspirin 100 mg daily or matching placebo; factorial assignment also included n-3 fatty acids or placebo.
- Primary efficacy outcome was first serious vascular event (myocardial infarction, stroke or transient ischemic attack, or vascular death, excluding confirmed intracranial hemorrhage); primary safety outcome was first major bleeding event.
- Intention-to-treat time-to-event analyses used log-rank methods; mean follow-up was 7.4 years, with estimated mean adherence 70% in each group.
Limitations
- Stated: analyses for cancer had limited statistical power to detect hypothesized effects, and longer-term follow-up is planned or being continued.
- Stated: intention-to-treat analyses underestimate the effects of actual aspirin use because adherence was incomplete; secondary and exploratory outcomes were not adjusted for multiple comparisons, so confidence intervals should not be used to infer definitive subgroup or secondary effects.
- Evident from the text: participants were predominantly white (96.5%), had type 2 diabetes (94.1%), were recruited in the United Kingdom, and were well treated with cardioprotective therapies (e.g., 75.6% statin use in the aspirin group), which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
14 Valid · 1 Not valid · 4 Not checked · 53 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Aspirin use reduces the risk of occlusive vascular events but increases the risk of bleeding; the balance of benefits and hazards for the prevention of first cardiovascular events in patients with diabetes is unclear.”
What the sources say
- Supportedcites [1] 1. Antithrombotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60. source
The Results report fewer serious vascular events with aspirin in both primary and secondary prevention trials. The Abstract’s Interpretation explicitly describes a reduction in occlusive events, while noting that bleeding risk must be weighed against this benefit in primary prevention. (LLM, conf=0.94)
- Supportedcites [2] 2. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011; 124: 2458-73. source
The Antiplatelet agents/anticoagulants recommendations (page not provided) recommend aspirin for patients with coronary artery disease and state that it reduces saphenous vein graft closure after bypass surgery. This supports the attributed claim that aspirin reduces occlusive vascular events in the guideline’s secondary-prevention setting; the separate statement about first events in diabetes is not part of the quoted claim. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“On average, however, the approximate 50% higher risk of bleeding with aspirin use than with control counterbalanced much of the benefit in these low-risk patients.”
What the sources say
- Supportedcites [1] 1. Antithrombotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60. source
The Results report about a 50% increase in major gastrointestinal and other extracranial bleeding with aspirin in primary-prevention trials (RR 1.54). The Discussion says aspirin’s absolute benefits are much smaller in primary than in secondary prevention and that its benefits and bleeding hazards can be approximately balanced, supporting the claim about low-risk patients. (LLM, conf=0.93)
plainstates a causen = 95,000- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Only approximately 4% of participants in those trials had diabetes, and the lower relative risk among them was similar to that observed among participants without diabetes (as was also observed in the context of secondary prevention).”
What the sources say
- Partly supportedcites [1] 1. Antithrombotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says that, in the primary-prevention trials, the proportional reduction in serious vascular events did not differ significantly by history of diabetes. This supports the main comparison, but the passages do not establish the citing sentence’s approximately 4% figure or its diabetes-specific comparison in secondary prevention. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The 2009 Antithrombotic Trialists' Collaboration meta-analysis involving 95,000 patients in six primary prevention trials showed that assignment to aspirin use led to a 12% (95% confidence interval [CI], 6 to 18) lower risk of serious vascular events than control. 1”
What the sources say
- Supportedcites [1] 1. Antithrombotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60. source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a causen = 95,000- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Aspirin use reduces the risk of occlusive vascular events but increases the risk of bleeding; the balance of benefits and hazards for the prevention of first cardiovascular events in patients with diabetes is unclear.”
What the sources say
- Supportedcites [1] 1. Antithrombotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60. source
The Results report that aspirin increased major gastrointestinal and other extracranial bleeds in primary prevention trials, with a significant excess of major bleeds also observed in secondary prevention trials. This supports the attributed claim that aspirin increases bleeding risk. (LLM, conf=0.94)
- Partly supportedcites [2] 2. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011; 124: 2458-73. sourceExperimental — accuracy not yet measured
The Antiplatelet agents/anticoagulants recommendations (page unavailable) state that warfarin used with aspirin and/or clopidogrel is associated with increased bleeding risk. The References also list a study of bleeding complications at different aspirin doses, but the guideline passage does not establish the unqualified claim that aspirin use alone increases bleeding risk. (LLM, conf=0.81)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
37 more claims · 6 with their cited sources checked
Create a free account to see all 72 claims and every source verdict.
- It may state two separate claims as one. 16
- Probably not a substantial claim. 19
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The benefit of ASA in the ASCEND trial was observed on top of statins (75% of patients) and/or anti-hypertensive (∼60% of patients) drugs.292”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [292]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For people > 70 years of age (with or without diabetes), the balance appears to have greater risk than bene fi t (144,146).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [144]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“however, the ASCEND trial found benefit of low-dose aspirin in those in this weight range, which would not validate this suggested hypothesis (179).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [179]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For people >70 years of age (with or without diabetes), the balance appears to have greater risk than benefit (179,181).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [179]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There were no significant differences by sex, weight, or duration of diabetes or other baseline factors, including ASCVD risk score.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [179]
Experimental — accuracy not yet measured
17 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
Rivaroxaban with or without aspirin in stable cardiovascular disease
Eikelboom, J. W., Connolly, S. J., Bosch, J., Dagenais, G. R., Hart, R. G., Shestakovska, O., Diaz, R., Alings, M., Lonn, E. M., Anand, S. S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709118 · Cited by 2,438
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
Smith, S. C., Benjamin, E. J., Bonow, R. O., Braun, L. T., Creager, M. A., Franklin, B. A., Gibbons, R. J., Grundy, S. M., Hiratzka, L. F., Jones, D. W., et al. (2011) · Circulation · doi:10.1161/cir.0b013e318235eb4d · Cited by 1,759
Rothwell, P. M., Fowkes, F. G. R., Belch, J. F., Ogawa, H., Warlow, C. P., & Meade, T. W. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62110-1 · Cited by 1,497
Rothwell, P. M., Wilson, M., Elwin, C.-E., Norrving, B., Algra, A., Warlow, C. P., & Meade, T. W. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61543-7 · Cited by 1,351
Rothwell, P. M., Wilson, M., Price, J. F., Belch, J. F., Meade, T. W., & Mehta, Z. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60209-8 · Cited by 984
Cited by
Items 601–700 of 1,171
Is the Benefit of Antithrombotics and Statins Worth the Risk of Intracerebral Hemorrhage? It Depends
Gutierrez, J. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.020460 · Cited by 5
Wolfe, R. S., Broder, J. C., Chan, A. T., Murray, A. M., Orchard, S. G., Polekhina, G., Ryan, J. L., Tonkin, A. M., Webb, K. L., & Woods, R. L. (2023) · medRxiv · doi:10.1101/2023.09.13.23295514 · Cited by 5
Cleland, J. G. F., & Anzar, D. (2025) · Clinical Trials · doi:10.1177/17407745251324865 · Cited by 5
Dobre, M.-Z., Vîrgolici, B., Doicin, I.-C., Vîrgolici, H., & Stănescu-Spînu, I.-I. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262010183 · Cited by 8
Mitochondrial oxidants promote platelet activation and thrombotic susceptibility in prediabetes
Ahmed, A., Yadav, P., Jensen, M., Geasland, K. M., Swamy, J., Spitz, D. R., Abel, E. D., Jalal, D. I., & Dayal, S. (2025) · Journal of Clinical Investigation · doi:10.1172/jci195662 · Cited by 7
Cancer Incidence and Mortality With Aspirin in Older Adults: Follow-Up of the ASPREE Trial
Orchard, S. G., Polekhina, G., Zalcberg, J. R., Bernstein, W. B., Macrae, F., Tie, J., Gately, L., Mar, V., Millar, J. L., Rodriguez, L. M., et al. (2026) · JAMA Oncology · doi:10.1001/jamaoncol.2025.6196 · Cited by 5
Agreement Between Mega-Trials and Smaller Trials: A Systematic Review and Meta-Research Analysis
Kastrati, L., Raeisi‐Dehkordi, H., Llanaj, E., Quezada‐Pinedo, H. G., Khatami, F., Ahanchi, N. S., Llane, A., Meçani, R., Muka, T., & Ioannidis, J. P. A. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.32296 · Cited by 7
Erlikh, A. D., Zilov, A. V., Shchekochikhin, D., Sb, S., Bublik, E. V., Игоревна, В. О., Grishkovets, A. I., Гамидович, Ф. А., & Ryzhkova, E. G. (2024) · Problems of Endocrinology · doi:10.14341/probl13414 · Cited by 8
de Jong, A. J., Zuidgeest, M. G. P., Santa‐Ana‐Téllez, Y., Hallgreen, C. E., van Sloten, T. T., de Boer, A., & Gardarsdóttir, H. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104304 · Cited by 6
Aspirin dosing after acute coronary syndrome with suspected aspirin resistance: the ANDAMAN trial
Dillinger, J., Pezel, T., Batias-Moreau, L., Angoulvant, D., Goralski, M., Ferrari, É., Cayla, G., Silvain, J., Gilard, M., Lemesle, G., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf680 · Cited by 7
Oller, D. A. (2020) · MedEdPORTAL · doi:10.15766/mep_2374-8265.10909 · Cited by 4
Armario, P., Brotons, C., Elosúa, R., de Leciñana, M. A., Castro, A., Clarà, A. B. I., Cortés, O., Rodríguez, Á. D., Herranz, M., Justo, S., et al. (2020) · PubMed Central · Cited by 5
Aspirin in primary prevention of cardiovascular disease in diabetes
Papazafiropoulou, A. K., Melidonis, A. J., & Antonopoulos, S. (2021) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad.2021.105596 · Cited by 5
Pharmacotherapy for Coronary Artery Disease and Acute Coronary Syndrome in the Aging Population
Moras, E., Zaid, S., Gandhi, K., Barman, N., Birnbaum, Y., Virani, S. S., Tamis‐Holland, J. E., Jneid, H. M., & Krittanawong, C. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01203-9 · Cited by 8
Frejková, M., Běhalová, K., Rubanová, D., Sanctis, J. B. D., Kubala, L., Chytil, P., Šimonová, A., Křížek, T., Randárová, E., Gunár, K., et al. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124742 · Cited by 5
Kang, S. H., Pack, K. M., Kim, J. H., & Jang, A. Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-87868-x · Cited by 5
Dillinger, J., Pezel, T., Batias-Moreau, L., Angoulvant, D., Goralski, M., Ferrari, É., Cayla, G., Silvain, J., Gilard, M., Lemesle, G., et al. (2025) · American Heart Journal · doi:10.1016/j.ahj.2025.04.016 · Cited by 5
Ferket, B. S., Hunink, M. G. M., Masharani, U. B., Max, W. B., Yeboah, J., & Fleischmann, K. E. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.041543 · Cited by 5
A farewell to aspirin in primary prevention?
Montalescot, G. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0148-z · Cited by 5
Plazak, M. E., Mouradjian, M. T., Watson, K., Reed, B. N., Noel, Z. R., Devabhakthuni, S., & Gale, S. E. (2019) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2019.1642108 · Cited by 4
Aspirin in Primary Prevention: Needs Individual Clinical Judgments
Gitin, A., Pfeffer, M. A., DeMets, D. L., & Hennekens, C. H. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.01.006 · Cited by 5
Utilisation et gestion des inhibiteurs de la pompe à protons : une étude observationnelle
Gramont, B., Bertoletti, L., Roy, M., Roblin, X., Tardy, B., & Cathébras, P. J. (2020) · Therapies · doi:10.1016/j.therap.2020.03.002 · Cited by 4
Targeting multiple domains of residual cardiovascular disease risk in patients with diabetes
Patel, K. V., & Vaduganathan, M. (2020) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000762 · Cited by 4
Point-of-Care Ultrasound (POCUS) in the Field of Diabetology
Vandemergel, X. (2021) · International Journal of Chronic Diseases · doi:10.1155/2021/8857016 · Cited by 8
Obesity 2021: Current Clinical Management of a Chronic, Serious Disease
Kushner (2021) · The Journal of Family Practice · doi:10.12788/jfp.0221 · Cited by 8
Synthesis of a polyacetylene derivative bearing aspirin with chiral charge carrier “chiralions”
Ichikawa, M., & Goto, H. (2021) · Journal of Macromolecular Science Part A · doi:10.1080/10601325.2021.1981765 · Cited by 4
Balletshofer, B. M., Böckler, D., Diener, H., Heckenkamp, J., Ito, W. D., Katoh, M., Lawall, H., Malyar, N. M., Oberländer, Y., Reimer, P., et al. (2022) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1624-3631 · Cited by 6
Prevention of Coronary Artery Disease in Women
Liu, E., Bigeh, A., Ledingham, L., & Mehta, L. S. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01721-5 · Cited by 4
Resumption of Antiplatelet Therapy after Major Bleeding
Geisler, T., Poli, S., Huber, K., Rath, D., Aidery, P., Kristensen, S. D., Storey, R. F., Ball, A., Collet, J., & ten Berg, J. M. (2022) · Thrombosis and Haemostasis · doi:10.1055/s-0042-1750419 · Cited by 4
Lipoprotein(a)—When to Screen and How to Treat
Patel, N., Mittal, N., Choubdar, P. A., & Taub, P. R. (2022) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-022-00698-8 · Cited by 4
Primary and secondary prevention of atherosclerotic cardiovascular disease: A case-based approach
Hariri, E. H., Hammoud, M. M. A., Nissen, S. E., & HAMMER, D. F. (2022) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.89a.21103 · Cited by 6
Evaluation of a Pharmacist-Driven Ambulatory Aspirin Deprescribing Protocol
Rothbauer, K., Siodlak, M. M., Dreischmeier, E., Raňola, T. S., & Welch, L. L. (2022) · Federal Practitioner · doi:10.12788/fp.0294 · Cited by 8
Erukulapati, R. S., Ganguri, M., Menon, A. S., Ayyagari, U., Jayapaul, M. K., Gurazada, K. C., Nalla, S., Srinath, A., Sampath, S. K., Manohar, S. P., et al. (2023) · Clinical Diabetology · doi:10.5603/dk.a2022.0061 · Cited by 6
Diabetes mellitus und kardiovaskuläre Prävention
Kellerer, M., & Qiu, H. J. (2023) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1928-1360 · Cited by 6
Do We Still Need Aspirin in Coronary Artery Disease?
Maqsood, M. H., Levine, G. N., Kleiman, N. S., Hasdai, D., Uretsky, B. F., & Birnbaum, Y. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12247534 · Cited by 5
Age and Aspirin Dosing in Secondary Prevention of Atherosclerotic Cardiovascular Disease
Marquis‐Gravel, G., Stebbins, A., Wruck, L. M., Roe, M. T., Effron, M. B., Hammill, B. G., Whittle, J., VanWormer, J. J., Robertson, H. R., Alikhaani, J. D., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.122.026921 · Cited by 7
Wang, J., Zhang, Y., Wu, Q., Bian, Z., Luo, N., Sun, J., Yu, B., & Fang, J. (2024) · PLoS ONE · doi:10.1371/journal.pone.0302228 · Cited by 8
Aspirin for primary prevention of CVD: a matter of balance
Fernández-Ruíz, I. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0096-7 · Cited by 4
Ikram, A., & Zafar, A. (2019) · StatPearls · Cited by 5
Primary prevention of myocardial infarction: aspirin is not as useful as it seems
Luan, Y., Li, Y., Zhao, L., Zhang, W., & Fu, G. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.02.70 · Cited by 5
Aspirin in a diabetic retinopathy setting: Insights from NO BLIND study
Pafundi, P. C., Galiero, R., Caturano, A., Acierno, C., de Sio, C., Vetrano, E., Nevola, R., Gelso, A., Bono, V., Costagliola, C., et al. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.06.021 · Cited by 4
Necessity of Antiaggregation and Anticoagulation and Its Prognostic Impact: A Cardiologist’s View
Hink, U., & Voigtländer, T. (2020) · Visceral Medicine · doi:10.1159/000509896 · Cited by 8
Rey, J. R., Merino, J. L., Iniesta, Á. M., et al. (2020) · Revista Española de Cardiología · doi:10.1016/j.recesp.2020.09.003 · Cited by 4
Aile hekimliği polikliniğine başvuran hastalarda Aspirin kullanımının değerlendirilmesi
Acar, A. B., & Özen, M. (2021) · Çukurova medical journal (Online)/Çukurova medical journal · doi:10.17826/cumj.907395 · Cited by 4
Screening for Autoantibodies in Type 1 Diabetes: A Call to Action
Петерс (2021) · The Journal of Family Practice · doi:10.12788/jfp.0223 · Cited by 11
Fortuni, F., Crimi, G., Gritti, V., Mirizzi, A. M., Leonardi, S., & Ferrari, G. M. D. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319826439 · Cited by 4
Barry, A. R., Semchuk, W., Thompson, A., LeBras, M. H., & Koshman, S. L. (2020) · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada · doi:10.1177/1715163520909137 · Cited by 5
Primary Prevention of Cardiovascular Disease Guidelines
Sajja, A. P., Alfaddagh, A., & Blumenthal, R. S. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56279-3_26 · Cited by 4
Nicolas, J., Razuk, V., Giustino, G., & Mehran, R. (2021) · Future Cardiology · doi:10.2217/fca-2021-0014 · Cited by 5
Pragmatic Clinical Trials—Ready for Prime Time?
Rifai, M. A., Itchhaporia, D., & Virani, S. S. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.40212 · Cited by 5
Choi, K. H., Kang, D., Nam, J., Park, T. K., Song, M. G., Seo, T.-S., Yang, W. J., & Choi, S. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.125.044102 · Cited by 4
Inherited risk of coronary artery disease: redefining care with imaging and genetics
Lan, N. S. R., Dwivedi, G., Hillis, G. S., Chew, D. P., Yeap, B. B., Figtree, G. A., Khera, A. V., Watts, G. F., & Ihdayhid, A. R. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01254-2 · Cited by 4
More Evidence to Help Guide Decision Making About Aspirin for Primary Prevention
Pignone, M. P., & DeWalt, D. A. (2018) · Annals of Internal Medicine · doi:10.7326/m18-2637 · Cited by 3
Rey, J. R., Merino, J. L., Iniesta, Á. M., et al. (2020) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2020.09.020 · Cited by 3
Wilkinson, J. J., & Tromp, K. M. (2017) · The American Pharmacists Association eBooks · doi:10.21019/9781582122656.ch5 · Cited by 3
Kim, S. P., Ryu, J., Kim, S. H., & Yoon, H. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.03.009 · Cited by 3
Varghese, C. J., Grunske, M., & Nagy, M. W. (2024) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2024.228 · Cited by 3
Kazibwe, R., Singleton, M. J., Bancks, M. P., Namutebi, J. H., Hammoud, A., Shapiro, M. D., & Yeboah, J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15753 · Cited by 5
Aspirin for colorectal cancer chemoprevention: where are we?
Genoud, V., Kim, F., & Koessler, T. (2025) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001153 · Cited by 3
Practical Considerations in the Management of Frail Older People with Diabetes
Abdelhafiz, D., & Abdelhafiz, A. H. (2025) · Diseases · doi:10.3390/diseases13080249 · Cited by 10
Hawkey, C. J., Avery, A. J., Coupland, C. A. C., Crooks, C. J., Dumbleton, J., Hobbs, R. F., Kendrick, D., Moore, M. V., Morris, C. D., Rubin, G. P., et al. (2025) · Health Technology Assessment · doi:10.3310/llkf7871 · Cited by 4
Medical therapeutics: mortality effects, uncertainty, and informed consent
Nunes, J. P. L. (2019) · Porto Biomedical Journal · doi:10.1097/j.pbj.0000000000000035 · Cited by 3
Clinical trials in long-term antiplatelet therapies: focus on the role of aspirin
Goel, R., & Baber, U. (2019) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000640 · Cited by 3
Use of cardiovascular imaging in risk restratification of the diabetic patient
Bellinge, J. W., Lee, S. C., & Schultz, C. J. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000611 · Cited by 3
Ippen, F. M., Walter, F., Hametner, C., Gumbinger, C., Nagel, S., Purrucker, J. C., & Mundiyanapurath, S. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.644223 · Cited by 3
Reconsidering the Polypill for Management of Cardiovascular Risk Factors in Underserved Patients
Macaulay, T. E., Sheridan, E. A., & Ward, S. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01448-9 · Cited by 3
Comments on the 2021 ESC guidelines on cardiovascular disease prevention in clinical practice
Arrarte, V., Campuzano, R., Duque, J. A. A., Aldama, G., Barrios, V., Bonanad, C., Conde, A. C., Olmo, R. F., Gámez, J. M., Guzmán, G., et al. (2022) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2021.10.023 · Cited by 5
Hong, S., Lee, W. J., & Park, C.-Y. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2021.1353 · Cited by 3
An antiplatelet response gene expression signature is associated with bleeding
Friede, K. A., Myers, R. A., Gales, J., Zhbannikov, I. Y., Ortel, T. L., Shah, S. H., Kraus, W. E., Ginsburg, G. S., & Voora, D. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac079 · Cited by 3
Diabetes: how to manage cardiovascular risk in secondary prevention patients
Anderson, S. L., & Marrs, J. C. (2022) · Drugs in Context · doi:10.7573/dic.2021-10-1 · Cited by 3
Mehta, A., Jain, P., Patil, R., Kant, T. S., Indurkar, S. A., Kota, S. K., Revankar, S. Y., & Gupta, A. (2022) · Cureus · doi:10.7759/cureus.31468 · Cited by 6
Aspirin in diabetic patients at primary prevention: insights of the VITAL cohort
Caldeira, D., Alves, M., Ferreira, J. J., et al. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-02001-3 · Cited by 3
Lin, Y., Chen, B., Chen, W., Chien, L., & Huang, C. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.14134 · Cited by 3
Catarci, M., Tritapepe, L., Rondinelli, M. B., Beverina, I., Agostini, V. W., Buscemi, F., Amisano, M. F., Attinà, G. M., Baldini, G., Cerutti, A., et al. (2024) · Il Giornale di Chirurgia - Journal of the Italian Association of Hospital Surgeons · doi:10.1097/ia9.0000000000000041 · Cited by 7
Effect of Low-Dose Aspirin on the Elderly
Darraj, A. (2024) · Cureus · doi:10.7759/cureus.54658 · Cited by 4
Primary Prevention of Cardiovascular Disease in Women
Shahid, I., Avenatti, E., Titus, A., Al-Kindi, S. G., & Nasir, K. (2024) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcvj.1313 · Cited by 8
Bruun-Jensen, M., Winther, S., Schmidt, S. E., & Dahl, C. M. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-076640 · Cited by 4
Masutani, N., Ogawa, H., Soejima, H., Okada, S., Masuda, I., Waki, M., Jinnouchi, H., Saito, Y., & Morimoto, T. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00679-9 · Cited by 4
Hu, H., Chen, W.-J., Xiong, Z.-Y., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-75612-w · Cited by 3
Reassessing the role of aspirin in patients with coronary artery disease
Tantry, U. S., Becker, R. C., Singh, S., Raghavakurup, L., Navarese, E. P., Bliden, K. P., & Gurbel, P. A. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2427338 · Cited by 4
Use of Aspirin and Initial Cardiovascular and Bleeding Risk in Patients with Chronic Kidney Disease
Kim, J. Y., Lim, H., Park, C. H., Kim, H. W., Chang, T. I., & Han, S. H. (2024) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000619 · Cited by 3
Giannopoulou, E. Z., Rallidis, L. S., Tsamoulis, D., Gianniou, M., & Kosmas, C. E. (2024) · Drugs in Context · doi:10.7573/dic.2024-10-2 · Cited by 2
Review of the top 5 cardiology studies of 2017-18
Barry, A. R., Babadagli, H. E., Chen, J. W., May, T. A., McMillan, C. L., Omar, M. A., Pollmann, D. M., Zhou, J. S., & Ackman, M. L. (2019) · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada · doi:10.1177/1715163519882464 · Cited by 3
Antithrombotic Management After Intracranial Hemorrhage
Cajavilca, C. E., Hooper, D., Imran, R., & Gadhia, R. R. (2019) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-019-0771-y · Cited by 3
Direct Oral Anticoagulants and Coronary Artery Disease: The Debacle of the Aspirin Era?
García‐Ropero, Á., Vargas-Delgado, A. P., Santos‐Gallego, C. G., & Badimón, J. J. (2020) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000795 · Cited by 3
Khalili, M., Lepeytre, F., Guertin, J. R., Goupil, R., Troyanov, S., Bouchard, J., & Madore, F. (2020) · CMAJ Open · doi:10.9778/cmajo.20190105 · Cited by 3
Misialek, J. R., Hof, J. V., Oldenburg, N. C., Jones, C., Eder, M., Luepker, R. V., & Duval, S. (2020) · Journal of Community Health · doi:10.1007/s10900-020-00798-9 · Cited by 3
Prior Use of Medication for Primary Prevention in Patients with Coronary Syndrome
Gaviria‐Mendoza, A., Zapata-Carmona, J. A., Bastidas, A. A. R., Pulgarín, C. L. B., & Machado‐Alba, J. E. (2020) · Journal of Primary Care & Community Health · doi:10.1177/2150132720946949 · Cited by 4
M’Pembele, R., Metzen, D., Czychy, N., Zako, S., Mourikis, P., Helten, C., Trojovsky, K., Ignatov, D., Petzold, T., Thienel, M., et al. (2021) · Diabetic Medicine · doi:10.1111/dme.14532 · Cited by 3
Burns, R. B., Pignone, M. P., Michos, E. D., & Kanjee, Z. (2021) · Annals of Internal Medicine · doi:10.7326/m21-2596 · Cited by 4
O’Malley, D. M., Blair, C. K., Greenbaum, A., Wiggins, C. L., Rajput, A., Chiu, V. K., & Kinney, A. Y. (2022) · Journal of Community Genetics · doi:10.1007/s12687-021-00574-9 · Cited by 4
Pinto, R. D., Pietropaoli, D., Desideri, G., & Ferri, C. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.6952 · Cited by 3
Sarejloo, S., Dehghani, F., Hatamnejad, M. R., Jahangiri, S., Ghaedian, T., Salimi, M., & Drissi, H. B. (2023) · ARYA Atherosclerosis · doi:10.48305/arya.2022.11824.2494 · Cited by 3
What have we learned about using aspirin for primary prevention from the ASCEND and ARRIVE trials?
Tousoulis, D. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy281 · Cited by 3
The cardiovascular benefits of low-dosage acetylsalicylic acid
Koilpillai, P., & Nishtala, N. S. (2019) · Canadian Medical Association Journal · doi:10.1503/cmaj.191037 · Cited by 3
Manzocco, M., Delitala, A., Serdino, S., Manetti, R., & Scuteri, A. (2019) · Aging Clinical and Experimental Research · doi:10.1007/s40520-019-01387-0 · Cited by 4
Antithrombotic effect of different acetylsalicylic acid drug formulations: is there a difference?
Сидоров, А. В. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2021-4734 · Cited by 5
Balletshofer, B. M., Böckler, D., Diener, H., Heckenkamp, J., Ito, W. D., Katoh, M., Lawall, H., Malyar, N. M., Oberländer, Y., Reimer, P., et al. (2021) · Diabetologie und Stoffwechsel · doi:10.1055/a-1515-9190 · Cited by 4
Chen, K.-H., Wang, T.-Y., Lee, C.-P., Yang, Y., McIntyre, R. S., Subramaniapillai, M., Lee, Y. L., & Chen, V. C. (2022) · Medicine · doi:10.1097/md.0000000000029202 · Cited by 3
Variability in aspirin efficacy: all in the genes?
Baigent, C., & Holmes, M. V. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz456 · Cited by 4
Metadata
- Authors
- The ASCEND Study Collaborative Group
- Affiliations
- MRC Population Health Research Unit (GB)
- Corresponding author
- The ASCEND Study Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-10-18
- Volume
- 379
- Issue
- 16
- Pages
- 1529-1539
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899755710
- Cited by
- 1,200
- References
- 23
- Citations by year
- 2026: 66 · 2025: 105 · 2024: 123 · 2023: 117 · 2022: 170 · 2021: 176 · 2020: 193 · 2019: 214 · 2018: 33
- FWCI
- 116.42
- Type
- journal article
- Language
- en
- Open access
- green
- ora.ox.ac.uk
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Oxford University Research Archive (ORA) (University of Oxford) (submittedVersion)
- Funders
- Mylan EPD
- Solvay Pharmaceuticals
- Bayer Schering
- British Heart Foundation (SP/03/02, SP/08/010/25939, SP/14/13/31114)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Keywords
- diabetes mellitus, aspirin, primary prevention, cardiovascular events, major bleeding, gastrointestinal bleeding, intracranial hemorrhage, myocardial infarction, stroke, cancer incidence, benefits and risks, ASCEND trial, occlusive vascular disease, antiplatelet therapy, cardiovascular risk reduction, gastrointestinal cancer, cancer mortality
- MeSH terms
- Aged, Aged, 80 and over, Aspirin, Cardiovascular Diseases, Diabetes Mellitus, Female, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Platelet Aggregation Inhibitors, Primary Prevention, Risk Factors, Poisson Distribution, Diabetes Complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-16, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-16 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.